Life-changing medications like Ozempic and Mounjaro are only approved right now for type 2 diabetes, but a growing body of evidence highlights the benefits of GLP-1s for people with type 1 diabetes.
Now, researchers are analyzing the data to see how GLP-1 drugs affect the risk of heart, kidney, and liver disease for people with type 1 diabetes. Focusing specifically on Mounjaro, a 2025 study in adults with type 1 diabetes and overweight or obesity found that after 21 months, participants experienced 23% weight loss, sustained improvements in glucose management, and significant improvements in blood pressure, cholesterol, triglycerides, and eGFR (a marker of kidney function). They also saw roughly a 16-fold decrease in the amount of total daily insulin needed.
“Such a huge decrease in insulin doses puts people at risk of DKA and hypoglycemia, but none of them were reported, at least in this cohort,” said Dr. Satish Garg, a professor at the Barbara Davis Center for Diabetes and lead author on the study.
Now, researchers are analyzing the data to see how GLP-1 drugs affect the risk of heart, kidney, and liver disease for people with type 1 diabetes. Focusing specifically on Mounjaro, a 2025 study in adults with type 1 diabetes and overweight or obesity found that after 21 months, participants experienced 23% weight loss, sustained improvements in glucose management, and significant improvements in blood pressure, cholesterol, triglycerides, and eGFR (a marker of kidney function). They also saw roughly a 16-fold decrease in the amount of total daily insulin needed.
“Such a huge decrease in insulin doses puts people at risk of DKA and hypoglycemia, but none of them were reported, at least in this cohort,” said Dr. Satish Garg, a professor at the Barbara Davis Center for Diabetes and lead author on the study.
Last edited:
